礼来公司的Retatrutide使肥胖骨关节炎成人平均减重71磅，膝盖疼痛减轻。 Eli Lilly's retatrutide caused 71-pound average weight loss and reduced knee pain in obese adults with osteoarthritis.

伊利利利的实验药物雷塔胺,一种针对GLP-1,GIP和葡萄糖的三重激素激动剂,在3期试验中,在68周内,平均体重减轻28.7% - - 约71磅 - - 参与肥胖和膝关节骨关节炎的成年人. Eli Lilly’s experimental drug retatrutide, a triple hormone agonist targeting GLP-1, GIP, and glucagon, led to an average weight loss of 28.7%—about 71 pounds—over 68 weeks in a Phase 3 trial involving adults with obesity and knee osteoarthritis. 该药物还将膝盖疼痛减少多达75.8%,并改进心血管风险标记,12%至14%的病人完全缓解了疼痛。 The drug also reduced knee pain by up to 75.8% and improved cardiovascular risk markers, with 12% to 14% of patients achieving complete pain relief. 诸如恶心和腹泻等副作用导致18%最高剂量的病人停止治疗,一些人将过重减重作为原因。 Side effects like nausea and diarrhea caused 18% of patients on the highest dose to discontinue treatment, and some cited excessive weight loss as a reason. 结果优于现有减重药物,支持了肥胖症和骨髓炎治疗的潜在批准,预计2026年将再取得7个第三阶段的结果。 The results, which outperformed existing weight-loss drugs, support potential approval for obesity and osteoarthritis treatment, with seven additional Phase 3 results expected in 2026.